Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 59, Issue 21, Pages 9814-9824Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01086
Keywords
-
Categories
Funding
- Pharmasum Therapeutics AS of Tromso, Norway
- Norwegian Research Council [ES546707]
Ask authors/readers for more resources
DYRK1A has emerged as a potential target for therapies of Alzheimer's disease using small molecules. On the basis of the observation of selective DYRK1A inhibition by firefly D-luciferin, we have explored static and dynamic structural properties of fragment sized variants of the benzothiazole scaffold with respect to DYRK1A using X-ray crystallography and NMR techniques. The compounds have excellent ligand efficiencies and show a remarkable diversity of binding modes in dynamic equilibrium. Binding.geometries are determined in part by interactions often considered weak, including orthogonal multipolar types represented by, for-example, F-CO, sulfur aromatic, and halogen aromatic interactions, together with hydrogen bonds that are modulated by variation of electron withdrawing groups. These studies show how the benzothiazole scaffold is highly promising for the development of therapeutic DYRK1A inhibitors. In addition, the subtleties of the binding interactions, including dynamics, show how full structural studies are required to fully interpret the essential physical determinants of binding.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available